XAIR
Beyond Air, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$2.14
−1.16%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.15
From 52W high−95.63%
Volume6762.00
Market cap$2.10M
P/E (TTM)—
P/S (TTM)0.3x
Div yield—
Key dataOct 19, 2026
Open
$2.15
From 52W high
−95.63%
Volume
6762.00
Market cap
$2.10M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
31.0
MomentumView details →
1D Return
−1.16%
YTD Return
−84.99%
SummaryUpdated Jun 1, 2026
Beyond Air, Inc. (NASDAQ:XAIR) is a commercial-stage medical device and biopharmaceutical company founded in 2018 and based in Garden City, New York. The company was formerly known as AIT Therapeutics, Inc. before changing its name in June 2019. Beyond Air specializes in developing nitric oxide-based therapeutic solutions, with its flagship product being the LungFit platform - a revolutionary nitric oxide generator and delivery system that creates therapeutic nitric oxide from ambient air rather than requiring traditional gas cylinders.
Similar companies
Latest newsMore news →
Beyond Air announced preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026, its highest quarterly revenue, up approximately 30% sequentially and 27% year over year.12d agoBeyond Air, Inc. amended the employment agreement of Chief Financial Officer Daniel Moorhead, raising his annual base salary from $325,000 to $463,000 effective September 23, 2026.25d agoBeyond Air, Inc. entered into an employment agreement with Robert Goodman as Chief Executive Officer, effective September 23, 2026, providing an annual base salary of at least $650,000 and a target bonus of 60% of base salary.25d ago